Structure shares up 10.63% intraday after non-exclusive patent license agreement with Roche, securing $100M upfront payment.

Tuesday, Jan 13, 2026 10:48 am ET1min read
GPCR--
Structure surged 10.63% intraday trading, as the company announced a non-exclusive patent licensing agreement with Roche, securing a $100 million upfront payment on December 30, 2025. The company specializes in developing oral small molecule GPCR-targeted therapies, with its lead product Alinaprel for obesity treatment.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet